ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R.
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30.
IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE.
Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, Fernández-Murga ML.
Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024.
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S, Sun X, Zhou Z, Tang H, Xiao R, Lv Q, Wang B, Qu J, Yu J, Sun F, Deng Z, Tian Y, Li C, Yang Z, Yang P, Rao B.
Front Immunol. 2023 Sep 20;14:1235575. doi: 10.3389/fimmu.2023.1235575. eCollection 2023.
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination.
Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL, Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW.
Mol Cancer. 2023 Mar 30;22(1):63. doi: 10.1186/s12943-023-01753-7.
Pigeons (Columba livia) as Trainable Observers of Pathology and Radiology Breast Cancer Images.
Levenson RM, Krupinski EA, Navarro VM, Wasserman EA.
PLoS One. 2015 Nov 18;10(11):e0141357. doi: 10.1371/journal.pone.0141357. eCollection 2015.
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
Barraud S, Vacher S, Schiffler C, Wong J, Hamza A, Courtois L, Pinton A, Servant N, Baulande S, Attignon V, Soubeyran I, Rouleau E, Coussy F, Campone M, Legrand F, Jimenez M, André F, Bachelot T, Bièche I.
Br J Cancer. 2025 Sep;133(4):464-472. doi: 10.1038/s41416-025-03083-5. Epub 2025 Jun 12.
Conducive target range of breast cancer: Hypoxic tumor microenvironment.
Cheng W, Xiao X, Liao Y, Cao Q, Wang C, Li X, Jia Y.
Front Oncol. 2022 Sep 26;12:978276. doi: 10.3389/fonc.2022.978276. eCollection 2022.
PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.
Scerri J, Scerri C, Schäfer-Ruoff F, Fink S, Templin M, Grech G.
Front Endocrinol (Lausanne). 2022 Oct 18;13:1010092. doi: 10.3389/fendo.2022.1010092. eCollection 2022.
Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
Lötsch J, Sipilä R, Tasmuth T, Kringel D, Estlander AM, Meretoja T, Kalso E, Ultsch A.
Breast Cancer Res Treat. 2018 Sep;171(2):399-411. doi: 10.1007/s10549-018-4841-8. Epub 2018 Jun 6.
